Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2005 2
2006 2
2007 1
2008 3
2009 4
2010 3
2011 5
2012 3
2013 3
2014 6
2015 5
2016 5
2017 7
2018 10
2019 10
2020 8
2021 14
2022 15
2023 12
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Mahon KL, Sutherland SI, Lin HM, Stockler MR, Gurney H, Mallesara G, Briscoe K, Marx G, Higano CS, de Bono JS, Chi KN, Clark G, Breit SN, Brown DA, Horvath LG. Mahon KL, et al. Among authors: horvath lg. Prostate. 2024 Jun;84(8):747-755. doi: 10.1002/pros.24691. Epub 2024 Mar 27. Prostate. 2024. PMID: 38544345
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janát-Amsbury MM, Eggert T, Tran B. Dorff T, et al. Among authors: horvath lg. Clin Cancer Res. 2024 Apr 15;30(8):1488-1500. doi: 10.1158/1078-0432.CCR-23-2978. Clin Cancer Res. 2024. PMID: 38300720 Clinical Trial.
Correction to: Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post‑treatment unplanned hospital presentations: a randomised controlled trial.
Fethney J, Kim B, Boustany C, McKenzie H, Hayes L, Cox K, Simpson JM, Horvath LG, Vardy JL, McLeod J, Willcock S, Cook N, Acret L, White K. Fethney J, et al. Among authors: horvath lg. Support Care Cancer. 2024 Jan 17;32(2):110. doi: 10.1007/s00520-024-08326-4. Support Care Cancer. 2024. PMID: 38231349 Free PMC article. No abstract available.
Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post-treatment unplanned hospital presentations: a randomised controlled trial.
Fethney J, Kim B, Boustany C, McKenzie H, Hayes L, Cox K, Simpson JM, Horvath LG, Vardy JL, McLeod J, Willcock S, Cook N, Acret L, White K. Fethney J, et al. Among authors: horvath lg. Support Care Cancer. 2024 Jan 3;32(1):77. doi: 10.1007/s00520-023-08261-w. Support Care Cancer. 2024. PMID: 38170289 Free PMC article. Clinical Trial.
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Kelly WK, et al. Among authors: horvath lg. Cancer Discov. 2024 Jan 12;14(1):76-89. doi: 10.1158/2159-8290.CD-23-0964. Cancer Discov. 2024. PMID: 37861461 Free PMC article.
113 results